Amylyx Pharmaceuticals, Inc.
AMLXNASDAQHealthcareBiotechnology
Previous close
$38.66
−$1.00 · -2.52%
AMLX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
25
Expensive
Momentum
65
Gaining
Sentiment
73
Bullish
Risk resilience
64
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAmylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Joshua Cohen
- Listed since
- Jan 7, 2022
- Employees
- 136
Market position
Day range
Current $38.66
52-week range
Current $38.66
- Open
- $39.73
- Previous close
- $39.66
- Volume
- 4.64M
- 2.37× average
- Average volume
- 1.96M
- Average daily volume
- Market cap
- 4.3B USD
- Beta
- -0.21
- Market reference 1
- 50-day average
- $20.267
- +90.75% above average
- 200-day average
- $15.7351
- +145.69% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 921.66M USD
- P/E (TTM)
- -27.42×
- P/B (TTM)
- 17.97×
- P/S (TTM)
- 0×
- EV / EBITDA
- -6.39×
- Earnings yield
- -12.67%
- Free cash flow yield
- -10.81%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -47.41%
- Return on assets
- -43.51%
- Return on invested capital
- -49.26%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 14.27×
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -1059.08%
- 11 comparable reports
- Latest EPS result
- -0.39
- Estimate -0.36 · Miss by 8.06%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
11 ratingsAMLX news
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 28, 2018 | $0.42Quarterly | — | Apr 2, 2018 |
Dividend | Dec 28, 2017 | $0.36Quarterly | — | Jan 2, 2018 |
Dividend | Sep 28, 2017 | $0.24Quarterly | — | Oct 2, 2017 |
Ex-dividend Mar 28, 2018
$0.42
Quarterly
Payment Apr 2, 2018
Ex-dividend Dec 28, 2017
$0.36
Quarterly
Payment Jan 2, 2018
Ex-dividend Sep 28, 2017
$0.24
Quarterly
Payment Oct 2, 2017
AMLX peers
ETFs holding AMLX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM92.68M0.11%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI64.44M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 Growth ETFIWO33.67M0.22%15.16B USD0.24%$387.37+1.24%
iShares Biotechnology ETFIBB27.48M0.26%10.75B USD0.44%$213.56+1.29%
State Street SPDR S&P Pharmaceuticals ETFXPH23.51M4.19%560.87M USD0.35%$72.80+0.71%
Vanguard Extended Market ETFVXF19.81M0.02%93.7B USD0.05%$245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA16.14M0.07%23.1B USD0.03%$34.83+0.52%
iShares U.S. Pharmaceuticals ETFIHE12.35M0.72%1.74B USD0.37%$106.79+1.01%iShares Russell 2000 ETFIWM- Market value
- 92.68M
- Weight
- 0.11%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 64.44M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 Growth ETFIWO- Market value
- 33.67M
- Weight
- 0.22%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
iShares Biotechnology ETFIBB- Market value
- 27.48M
- Weight
- 0.26%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
State Street SPDR S&P Pharmaceuticals ETFXPH- Market value
- 23.51M
- Weight
- 4.19%
- AUM
- 560.87M USD
- Expense ratio
- 0.35%
- Price / 1D
- $72.80+0.71%
Vanguard Extended Market ETFVXF- Market value
- 19.81M
- Weight
- 0.02%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 16.14M
- Weight
- 0.07%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
iShares U.S. Pharmaceuticals ETFIHE- Market value
- 12.35M
- Weight
- 0.72%
- AUM
- 1.74B USD
- Expense ratio
- 0.37%
- Price / 1D
- $106.79+1.01%
Continue in GoAI
Research AMLXresearch.disclaimer